# TRILLIUM (NCT06456463)

> A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

No report yet. It can be ordered.

- Drugs tested: tagraxofusp plus venetoclax plus azacitidine
- Indication: previously untreated CD123+ acute myeloid leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06456463
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Stemline Therapeutics, Inc.
- Conditions: Acute Myeloid Leukemia
- Interventions: Tagraxofusp; Venetoclax; Azacitidine
- Enrollment: 85
- Primary outcome: Part 1: Determination of Part 2 Selected Dose of Tagraxofusp When Administered in Combination with Venetoclax and Azacitidine
- Primary outcome: Part 2: Number of Participants Achieving a Best Overall Response (BOR) of Complete Remission (CR)

## Indexed commentary on TRILLIUM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 1
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trillium-nct06456463